CHMP2B Polyklonaler Antikörper

• Featured Product
• KD/KO Validated

CHMP2B Polyklonal Antikörper für IF/ICC

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus, Ratte

Anwendung

IF/ICC

Konjugation

CoraLite® Plus 488 Fluorescent Dye

Kat-Nr. : CL488-12527

Synonyme

hVps2 2, DMT1, Chromatin-modifying protein 2b, chromatin modifying protein 2B, CHMP2.5

---

• 

  IF Staining of HepG2 using CL488-12527

  Immunofluorescent analysis of (-20°C Ethanol) fixed HepG2 cells using CoraLite® Plus 488 CHMP2B antibody (CL488-12527) at dilution of 1:200.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in IF/ICC: HepG2-Zellen

Empfohlene Verdünnung

• Immunfluoreszenz (IF)/ICC: IF/ICC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

CL488-12527 bindet in IF/ICC CHMP2B und zeigt Reaktivität mit human, Maus, Ratten

• Getestete Reaktivität: human, Maus, Ratte
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: CHMP2B fusion protein Ag3222
• Vollständiger Name: chromatin modifying protein 2B
• Berechnetes Molekulargewicht: 24 kDa
• Beobachtetes Molekulargewicht: 32 kDa
• GenBank-Zugangsnummer: BC001553
• Gene symbol: CHMP2B
• Gene ID (NCBI): 25978
• Konjugation: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission maxima wavelengths: 493 nm / 522 nm
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA
• Lagerungsbedingungen: Bei -20°C lagern. Vor Licht schützen. Nach dem Versand ein Jahr stabil. Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

CHMP2B, chromatin-modifying protein 2b, also named CHMP2.5, VPS2B, and VPS2 2, belongs to the chromatin-modifying protein / charged multivesicular body protein (CHMP) family. It is a component of the endosomal sorting complex required for transport III (ESCRT-III), which involves in endosomal and autophagic trafficking of proteins to lysosomes for degradation. Mutations of CHMP2B lead to C-terminal truncation or are replaced with mis-splicing C-termini and cause frontotemporal lobar degeneration (FTLD). In CHMP2B mutation patients, p62- and ubiquitin-positive, but TDP-43 and FUS negative neural inclusions are formed, which may be caused by impaired lysosomal degradation through the autophagy and endosome-lysosome pathways.